To include your compound in the COVID-19 Resource Center, submit it here.

NeuroVive reports preclinical data for cyclophilin D inhibitor program

NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) reported preclinical data showing that

Read the full 109 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE